Key facts
- It has raised $14.3M; the latest was Later Stage VC in Feb 2026.
- Notable investors include Shun Xi Fund, SJ Jiacheng Investment Management, Lotus Lake Ventures, ZGC Science City, SB China Venture Capital — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Beijing Huaguan Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Beijing Huaguan Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Beijing Huaguan Biotechnology
Developer of a pharmaceutical industrialization innovation platform intended for small molecular and ADC (Antibody-Drug-Conjugates). The company has a well-trained and experienced drug research and development team, and it has a variety of advanced experimental equipment to support pre-clinical pharmacy research, providing domestic and foreign pharmaceutical companies with integrated pharmaceutical R&D services.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2016
- Employees
- 200
- Website
- chempion.com.cn/
- Ownership
- Privately Held (backing)
Beijing Huaguan Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Beijing Huaguan Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Beijing Huaguan Biotechnology in its N-PORT filings yet. We sweep new filings monthly.